# GC012F

Source: https://onco.cc/drugs/gc012f/  
OnCo record `gc012f` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GC012F is an experimental CAR-T cell therapy from Gracell Biotechnologies (Shanghai) in phase 2 trials for multiple myeloma, aimed at CD19 and BCMA.

## Summary

GC012F is a CAR-T cell therapy developed by Gracell Biotechnologies (Shanghai). Its targets are CD19 and BCMA (the sponsor names BCMA x CD19). The sponsor states: A dual chimeric antigen receptor (CAR) T-cell product engineered to recognise and attack multiple myeloma cells expressing either BCMA or CD19. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in multiple myeloma. The largest, NCT06235229, plans to enrol 110 participants with primary completion was scheduled for 2026-03-02 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: CAR-T cell therapy
- Mechanism: A dual chimeric antigen receptor (CAR) T-cell product engineered to recognise and attack multiple myeloma cells expressing either BCMA or CD19.

## Sources

- ClinicalTrials.gov: trials of GC012F: https://clinicaltrials.gov/search?intr=GC012F

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [CD19](https://onco.cc/targets/cd19/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Gracell Biotechnologies](https://onco.cc/companies/gracell-biotechnologies/)
- trials: [A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct06235229/)

---
JSON: https://onco.cc/api/v1/entities/gc012f.json